Replies to post #111050 on Anavex Life Sciences Corp (AVXL)

[OFP]

...and it would also be very helpful to have an influential partner, such as Biogen, to help grease the skids...

When will the Biogen fantasy stop? They agreed to do testing for a "narrow indication" a year or so ago. That testing should have been done in a few weeks. That testing, AT BEST, would have added 2-73 to a substantial library of existing compounds that improve OPC differentiation. Given the deafening silence long after testing should be completed suggests they couldn't even make it into that library. No wonder Missling is starting to minimize the significance of the testing.

AVXL needs to do the hard work of getting real data if they want any hope of enticing any deep pockets.

[nidan7500]

helpful to have an influential partner

IMO, the shift in emphasis for the FDA trials away from massively expensive numbers based trails which go on for years. (note, such trials by default have favored BP).

Many will be unable to let go of the current CNS trials model for one that is based on a smaller/faster/deeper structure. Looking for one where trials success is based on all pts quality of life and not some minimal number of (acceptable)adverse events, such as those endured by AD patients for the past decades. There is no such thing as a "little" brain swelling. If I were BIIB I would be at a crossroads with this next step. What if they are conflicted by current investments and commits to the old school trials?

IMO, BIIB is fine as long as they can walk and chew gum. You are correct though we need their constructive buy in.